Esperion Therapeutics, Inc.
Here’s whether Esperion Therapeutics, Inc. (ESPR) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+4.16% over 10 days); RSI 60 — healthy momentum range; strong 1-year return of +169.8%. Concerns: declining volume on rally — weak conviction (0.60x 30d avg). Currently 25.0% off its 52-week high. Score: +5/7.
ESPR is in a confirmed uptrend, trading above both its 50-day ($2.68) and 200-day ($2.98) moving averages. An RSI of 60.0 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +169.8% compares to +24.4% for SPY (beat the market by 145.5%). The current 25.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.